Review: Geroscience Strategies to Delay Multiple Age-Related Diseases
This review describes geroscience approaches that aim to delay several age-related diseases at once by targeting shared biological aging processes, and it names translation challenges such as inconsistent efficacy across species and safety concerns in cellular reprogramming. [1]
Automatic summary · not editorially reviewed
The key findings
The review frames aging as a modifiable risk factor rather than an inevitability and discusses interventions targeting conserved biological drivers of aging. [1]
The review names inconsistent efficacy across species, safety concerns in cellular reprogramming and ethical debates over life versus health span as translation challenges. [1]
The review proposes a roadmap using artificial intelligence-driven drug discovery, organ-on-a-chip models and multiomics integration, and calls for integrating mechanistic discoveries into clinical practice. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Aging populations and age-related chronic diseases, discussed in a review
- Summary based on
- Study abstract
- Original publication
- March 16, 2026
Reframing aging as modifiable in this review
The review responds to rising aging populations and the growing burden of chronic age-related diseases. It frames aging as a modifiable risk factor rather than an inevitability. The described interventions aim to delay or prevent multiple age-related pathologies at the same time by targeting conserved biological drivers: genomic instability, epigenetic dysregulation, mitochondrial dysfunction and stem cell exhaustion. Senolytics and epigenetic reprogramming are given as examples of strategies meant to shift medicine from treating single diseases toward extending healthspan.
Supporting source [1]
Translation hurdles and sex-specific differences noted
The review addresses critical challenges in translation: inconsistent intervention efficacy across species, safety concerns in cellular reprogramming, and ethical debates over prioritizing life span versus health span. It also highlights sex-specific disparities in therapeutic outcomes and encourages precision-based approaches to ensure equitable benefits. These points are presented as issues to resolve, not as evidence that any intervention already works in people.
Supporting source [1]
Proposed roadmap using AI, organ-on-a-chip and multiomics
The review details a multidimensional roadmap intended to compress morbidity and redefine healthy aging. It proposes leveraging tools such as artificial intelligence-driven drug discovery, organ-on-a-chip models and multiomics integration. It calls for stronger integration of mechanistic discoveries into clinical practice, aiming at a paradigm of aging balanced on resilience and vitality rather than decline. These are proposals described in the review, not validated clinical products or proven human treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract describes proposed strategies and challenges but reports no study design, sample, follow-up or outcome data, so no efficacy in humans can be judged from it.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Pukar Khanal, Jagdish Chand, Vishal S. Patil, Lokjan Singh, Kunal Bhattacharya · doi.org · March 16, 2026